In the most recent Veeva Pulse Field Trends Report, published on July 25, 2024, Veeva Systems disclosed that medical affairs teams' influence on treatment adoption is considerably increased by targeted pre-launch scientific outreach. The report indicates that biopharmaceutical companies investing in pre-launch activities, such as congresses and clinical guidelines, experience 40% faster treatment adoption compared to those investing less. The analysis also highlights that early-career healthcare professionals (HCPs) are more receptive to digital engagement and are four times more likely to initiate patients on new treatments. Angela Smart from ADVANZ PHARMA emphasized the importance of expanding engagement strategies beyond traditional experts to include a broader range of stakeholders.
Veeva Pulse's analysis, based on over 600 million annual HCP interactions and activities, underscores that pre-launch congress activities have the strongest impact on clinical decisions post-approval. Engaging early-career HCPs, who are more likely to participate in digital discussions and congresses, significantly boosts new treatment uptake. Dan Rizzo, Vice President of Business Consulting at Veeva, stressed that effective communication of scientific evidence before launch is crucial. Veeva Systems, a global leader in cloud software for the life sciences industry, serves over 1,000 customers, including major biopharmaceutical companies and emerging biotechs. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders.
